A lipopolymer nanoparticle carrying siRNA, the Delmune delivery platform

Superior delivery.
Tamed inflammation.

We silence the inflammatory alarm at its source, inside the immune cells that raise it. Our carrier was built for those cells, because the delivery systems the field relies on cannot reach them without inflaming them first.

New: our technology is published in RSC Pharmaceutics, open access.

Two established fields. Neither has crossed into the other.

Crossing into the overlap means delivering genetic material into immune cells, which is the problem our carrier solves.

Gene silencingApproved and in wideclinical use.Every approved medicinein the class actson the liver.NLRP3-basedmedicinesValidated and alreadyin trials.Every clinical programoccupies the proteinrather than removing it.The overlapDELMUNESilencing NLRP3and otherinflammatory genesinside immune cells
Gene silencing and NLRP3-based medicines, and the overlap Delmune occupies.

Comparison

Two carriers compared.

Conventional lipid nanoparticle compared with the Delmune lipopolymer across six properties.
PropertyConventional lipid nanoparticleDelmune lipopolymer
How it is madeMicrofluidic mixing on specialised equipment. Batch-to-batch variation is a recognised risk when scaling up.Mixed by hand in half an hour at room temperature. Reproducible at any bench.
Where it ends upMostly the liver. Blood proteins coat it and a liver receptor pulls it in.Concentrates where immune cells are dense. The lung receives four times the liver dose.
Getting into immune cellsPoor. These cells exist to detect and reject foreign genetic material.Built for them. Roughly six times the uptake of a leading commercial reagent.
Effect on inflammationCan itself trigger the release of inflammatory signals, through the very alarm the drug must quiet.Leaves the main inflammatory messengers essentially unchanged in human blood cells.
Releasing the cargoOnly a small fraction of what enters a cell ever reaches the place it can work.Tuned to let go on arrival rather than hold on.
TolerabilityReactogenicity limits dosing in several clinical settings.Liver, kidney and blood chemistry unchanged after repeat dosing in animals.
Written for a reader who is not a bench scientist. The underlying measurements are on the publications page. (RSC Pharmaceutics 2026 · Adv Healthcare Mater 2025;14:e02019 · ACS Pharmacol Transl Sci 2024;7:2840 · Nat Immunol 2022;23:532–542)